Platelet-rich Plasma Intradermal Injection Combined With 308 nm Excimer Light for Treating Stable Acral Vitiligo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-22

Study Completion Date

2024-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if platelet-rich plasma (PRP) works to treat acral stable vitiligo in adults. It will also learn about the safety of platelet-rich plasma. The main questions it aims to answer are:

* Does PRP combined with 308 nm excimer phototherapy improve the efficacy compared to 308 nm excimer light alone in the treatment of vitiligo of the extremities?
* What medical problems do participants have when taking PRP intradermal injections?

Researchers will compare PRP to a placebo (a look-alike substance that contains no drug) to see if PRP works to treat acral vitiligo.

Participants will:

* Receive PRP intradermal injections once a month and 308 nm excimer phototherapy twice a week, or the same frequency of saline injections and phototherapy for 6 consecutive months
* Visit the clinic once every 1 month for evaluations
* Keep a diary of their symptoms or side effects during follow-up

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of AMG 714 for Vitiligo

NCT04338581

Vitiligo

COMPLETED PHASE2

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

NCT07251595

Non-segmental Vitiligo

RECRUITING PHASE2

Improved Phototherapy in Patients With Vitiligo

NCT05836441

Vitiligo

UNKNOWN NA

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

NCT04774809

Vitiligo

TERMINATED PHASE2/PHASE3

Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients

NCT06991972

Vitiligo Non-segmental Vitiligo

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vitiligo is an acquired skin disorder characterized by depigmented macules, and one of the conventional treatment principles is to promote the differentiation of stem cells at the follicular bulge into melanocytes, but vitiligo of the extremities is clinically difficult to repigmentation and resistant to treatment due to its lack of hair follicles. Platelet-rich plasma (PRP) is a concentrated platelet plasma obtained by in vitro isolation of autologous whole blood, and its effect on repigmentation of vitiligo at the extremities and the potential mechanism remain unclear. The investigators investigated the efficacy of PRP on acral vitiligo by a single-center, prospective, self-controlled clinical study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP+308nm

The observation group received PRP intradermal injections (0.5cm apart, 0.02ml injected) once a month and 308 nm excimer phototherapy twice a week for 6 consecutive months.

Group Type EXPERIMENTAL

PRP+308nm

Intervention Type COMBINATION_PRODUCT

PRP+308nm

NS+308nm

The control group received the same frequency of saline injections (0.5cm apart, 0.02ml injected) and phototherapy for 6 consecutive months.

Group Type PLACEBO_COMPARATOR

NS+308nm

Intervention Type COMBINATION_PRODUCT

NS+308nm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRP+308nm

Intervention Type COMBINATION_PRODUCT

NS+308nm

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non-segmental vitiligo stable for more than half a year;
* At least 1 separate stable lesion on each of the dorsum of the right and left hands, proximal fingers, distal fingers and palms;
* The area of white spots is less than 10 % of the total body surface area and more than 1 % of the total body surface area;
* Those who have not received systemic treatment of vitiligo and phototherapy or related treatments within 1 month ≥ 1 year without significant efficacy;
* Voluntary signing of informed consent.

Exclusion Criteria

* Pregnant and lactating women;
* Those who have used glucocorticoids or other immunosuppressants in the last 3 months;
* Suffering from haematological disorders such as coagulation abnormalities and thrombocytopoietic disorders;
* Those who are allergic to ultraviolet light and photosensitive treatment;
* Scar constitution;
* Those with current or previous history of skin cancer or family history of skin cancer;
* Those with infectious diseases such as HIV, syphilis, hepatitis B or C;
* Those with other serious systemic diseases;
* Patients who, in the judgement of the investigator, are not suitable for inclusion in this trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No